HDACi Platform (unspecified candidates)
Liquid Tumors (Leukemias, Lymphomas)
Key Facts
About Cetya Therapeutics
Founded in 2012 and based in Fort Collins, Colorado, Cetya Therapeutics is developing isoform-selective histone deacetylase inhibitors (HDACi) derived from largazole, a natural product. The company has nominated its lead candidate, CT-101, for the treatment of sickle cell disease, a significant unmet medical need. Cetya has strengthened its leadership with key board appointments and secured intellectual property through a process patent for its novel synthetic route, positioning itself to advance its pipeline.
View full company profileAbout Cetya Therapeutics
Founded in 2012 and based in Fort Collins, Colorado, Cetya Therapeutics is developing isoform-selective histone deacetylase inhibitors (HDACi) derived from largazole, a natural product. The company has nominated its lead candidate, CT-101, for the treatment of sickle cell disease, a significant unmet medical need. Cetya has strengthened its leadership with key board appointments and secured intellectual property through a process patent for its novel synthetic route, positioning itself to advance its pipeline.
View full company profile